Award4

Vivos Therapeutics, Inc.

Total Value

$2.2K

Filing Date

Sep 18, 2026

1 transactions

Trade Summary

On Sep 14, 2026, JOHNSON GREGG C, Director, reported $2.2K of Vivos Therapeutics, Inc. (VVOS) across 1 transactions. The filing covers company securities and reflects balanced net activity of $0. Reported prices ranged from $0.18. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: JOHNSON GREGG C
Role: Director
Location: LITTLETON, CO

Filing Details

Filing Date: Sep 18, 2026
Transaction Date: Sep 14, 2026
Accession Number: 0001493152-26-043441
Form Type: 4

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Sep 14, 2026	VVOS derivative	12,000	$0.18	Grant/Award	$2.2K

Want live alerts when JOHNSON GREGG C trades again?

Download Insider Trades to track VVOS, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)Shares held by Spite Family Holdings LP, an affiliate of the Reporting Person.
(F2)On September 14, 2026 (the "Grant Date"), the Reporting Person received a grant of 12,000 stock options from the Issuer. One-half vested immediately (and the earliest possible exercise date in Table II relates to this tranche), one-fourth will vest on September 30, 2026 and one-fourth will vest on December 31, 2026. The options are exercisable for a period of 10 years from the Grant Date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JOHNSON GREGG C

(Last)

(First)

(Middle)

7921 SOUTHPARK PLAZA,

SUITE 210

(Street)

LITTLETON

80120

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Vivos Therapeutics, Inc. [ VVOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock								3,997	I	See footnote⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)⁽²⁾	$0.18	09/14/2026		A		12,000		09/14/2026⁽²⁾	09/14/2036	Common Stock	12,000	$0	12,000	D

Explanation of Responses:

1. Shares held by Spite Family Holdings LP, an affiliate of the Reporting Person.

2. On September 14, 2026 (the "Grant Date"), the Reporting Person received a grant of 12,000 stock options from the Issuer. One-half vested immediately (and the earliest possible exercise date in Table II relates to this tranche), one-fourth will vest on September 30, 2026 and one-fourth will vest on December 31, 2026. The options are exercisable for a period of 10 years from the Grant Date.

	/s/ Bradford K. Amman as attorney-in-fact for Gregg C. Johnson	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001493152-26-043441.

Vivos Therapeutics, Inc.

Trade Summary

Company Information

Insider Information

Filing Details

Derivative Transactions

Want live alerts when JOHNSON GREGG C trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4